Hudson Bay Capital Management LP Clovis Oncology, Inc. Transaction History

Hudson Bay Capital Management LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 13, 2019	SELL	$3.93 - $15.35 $314,400 - $1.23 Million	-80,000 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$12.81 - $25.67 $256,200 - $513,400	20,000 Added 33.33%	80,000 $1.19 Million
Q1 2019 May 15, 2019	BUY	$17.66 - $30.28 $176,600 - $302,800	10,000 Added 20.0%	60,000 $1.49 Million
Q4 2018 Feb 13, 2019	SELL	$11.63 - $32.67 $1.35 Million - $3.79 Million	-116,100 Reduced 69.9%	50,000 $898,000
Q3 2018 Nov 14, 2018	BUY	$29.37 - $49.48 $3.41 Million - $5.74 Million	116,100 Added 232.2%	166,100 $4.88 Million
Q2 2018 Aug 13, 2018	SELL	$42.06 - $62.4 $420,600 - $624,000	-10,000 Reduced 16.67%	50,000 $2.27 Million
Q4 2017 Feb 12, 2018	BUY	$57.69 - $84.58 $1.15 Million - $1.69 Million	20,000 Added 50.0%	60,000 $4.08 Million
Q3 2017 Nov 13, 2017	BUY	$67.17 - $84.81 $2.69 Million - $3.39 Million	40,000	40,000 $3.3 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Hudson Bay Capital Management LP with notifications on news.